About this calendar Beta

This is a free biotech catalyst calendar built from a single source: what companies themselves write in their SEC filings. A scanner reads the 8-K and 6-K press releases that US-listed drug developers file on EDGAR, extracts every statement about an upcoming event — a data readout, a PDUFA decision, a conference presentation, a trial milestone — and records it in the company's own words, with a link to the filing it came from.

The rule that makes it different

We never guess a date. If a company said "September 2026", the calendar says September 2026. If it said "the second half of 2026", you see a six-month window, marked as such. Most catalyst calendars convert vague guidance into a specific-looking date; we think the width of the window is itself information — it tells you how much control the company has over its own timeline. The coloured tag on every row (day, month, quarter, half) is the precision the company actually gave.

The same rule applies when a window closes. If a company said "Q3" and the quarter has passed with no result and no new date in any filing, the event does not quietly disappear: it stays on the calendar with a red overdue tag for 45 days, under "Window closed, nothing filed since". This applies only where silence means something — guidance windows and regulatory dates. A presentation scheduled for a conference happens on its date whether or not it is filed about afterwards, so those are never marked overdue. A new date in a later filing replaces the old one (the company page shows the slip); a reported result retires it. Silence, we think, is information too.

What's on a company page

Each ticker page opens with the pipeline, from filings: one row per program the company itself has discussed in a filing in the last twelve months, with its stage and indication in the company's words, the next milestone it has dated, and when it last mentioned the program. Programs that go unmentioned for a year drop below a fold rather than lingering — a list of live programs, not of every trial ever registered. Then the upcoming catalysts; the statement history of every program — each filing that mentioned it, in order, so you can watch a timeline hold or slip; the company's own cash and runway statements, quoted; financings extracted from filings; the recent press-release filings themselves; and our cash estimate: the last company-stated cash figure, reduced by the company's average monthly spend for the months since, plus any raises we know arrived after. That estimate is ours, it is dated, and the company's own sentence is always printed beside it. Price, chart and market data are provided by TradingView.

What this is not

The calendar contains no recommendations, no price targets, and no predictions. It doesn't tell you whether a trial will succeed — nobody can from the outside — and a listing here is not an endorsement of the company. Analysis lives elsewhere: the BioStockInfo weekly scanner ranks the upcoming month's catalysts with a transparent six-part score and does the reading — the science, the competition, the balance sheet — on the names that score highest. Names covered there are marked on their ticker pages, together with what happened after we covered them; outcomes are tracked from the day of publication and reported in a quarterly review.

Corrections

Extraction is automated and filings are messy; a date can be misread or a program mislabelled. Every row links to its source so you can check us, and we'd rather hear about an error than have it stand: contact us via biostockinfo.com.

Forward-looking statements

Nearly everything quoted here is a forward-looking statement made by the company under the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's expectations on the filing date shown, involve substantial risks and uncertainties, and are routinely delayed, changed or withdrawn without notice.

Disclaimer

The information on this site is provided for informational purposes only and should not be construed as financial, investment, legal, or professional advice, nor as a recommendation to buy or sell any security. Clinical-stage biotechnology involves substantial risk: most drug candidates fail in development, regulatory decisions are unpredictable, companies may dilute shareholders at any time, and small-cap stocks experience extreme price swings. Do your own research, understand the science, and consult a licensed financial advisor before investing. Past performance does not guarantee future results. BioStockInfo and its authors may hold positions in securities mentioned; positions are disclosed in the weekly reports.